Educational Review

What is longevity medicine?

Longevity medicine is an emerging clinical field that aims to extend healthspan, the years lived in good health, rather than lifespan alone. It applies geroscience, the study of how ageing drives chronic disease, to prevention, early detection and risk reduction. Its best-supported components draw on established preventive care; many of its newer tools remain unproven.

Educational content for healthcare professionals. It is not advice for patients.

How do experts define longevity medicine?

There is no single agreed definition yet. Published descriptions share one idea: clinical care aimed at keeping people healthy for longer, guided by the biology of ageing.

Two 2021 commentaries discussed longevity medicine, one on artificial intelligence and one on training physicians [1][2]. A 2024 review calls longevity medicine “an emerging and iterative healthcare discipline” focused on early detection and prevention, and on extending the span of healthy life [4]. A 2026 study describes healthy longevity medicine as “an emerging clinical framework aimed at optimizing health span”, grounded in geroscience [3].

The key word is healthspan: unlike lifespan, it counts only the years lived in good health, free of serious disease and disability [5]. A 2024 analysis of 183 World Health Organization (WHO) member states found a global average gap of 9.6 years between the two in 2019 [5]. WHO frames the goal as healthy ageing: “the process of developing and maintaining the functional ability that enables wellbeing in older age” [6].

This matters in India, which had 149 million people aged 60 and above in 2022, about 10.5 percent of the population. By 2050 this is projected to reach 347 million, or 20.8 percent [7].

What is the science behind it?

The scientific basis is the geroscience hypothesis. It holds that ageing itself is the main risk factor for most chronic diseases, so slowing ageing biology might delay several diseases at once [8].

A 2014 paper in Cell called ageing “the greatest risk factor for a majority of chronic diseases”. It noted that interventions extending lifespan in model organisms often delay many chronic diseases, evidence that comes mainly from animals [8].

Researchers group the biology of ageing into “hallmarks”. A 2023 update lists twelve, including genomic instability (accumulating DNA damage), cellular senescence (cells that stop dividing but stay active) and chronic inflammation [9]. These hallmarks are research targets, not routine clinical tests.

What does longevity medicine cover in practice?

Its best-supported components overlap with established preventive care [3]. These span cardiometabolic health, fitness, sleep and nutrition, plus a newer interest in measuring biological ageing.

The American Heart Association’s well-supported Life’s Essential 8 checklist covers diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose and blood pressure [10].

Exercise capacity is a strong marker of future health. In 122,007 adults who had treadmill tests, lower cardiorespiratory fitness (the body’s ability to supply oxygen during exercise) was linked to higher death rates [11]. The least fit had about five times the death risk of the fittest, a gap at least as large as that linked to smoking or diabetes [11]. This observational study shows association, not proof of cause.

Can biological age be measured?

It can be estimated, but commercial biological-age scores are not established substitutes for validated clinical risk assessment, and their use to select anti-ageing treatments remains insufficiently validated [14]. Epigenetic clocks are promising research measures.

Biological age is an estimate of how far the body has aged, as distinct from years since birth. Epigenetic clocks estimate it from DNA methylation, a chemical tagging of DNA that changes with age. Some clocks are trained across multiple tissues; others are tissue-specific [12].

A 2022 study found that technical noise alone shifted results by up to 9 years between repeat samples for six widely used conventional clocks [13]. The same authors built revised versions, called PC clocks, that filter out much of this noise, bringing most repeat samples within 1.5 years [13]. A 2024 expert review noted that “no consensus exists” on how ageing biomarkers should be validated before clinical use [14].

What is established, and what is still being tested?

The evidence ranges from well established to experimental, and spans all four evidence labels.

  • Established Evidence (clinical approaches supported by sufficiently developed evidence and accepted professional practice): controlling blood pressure, lipids and glucose, avoiding tobacco, and supporting physical activity, diet and sleep [10].

  • Developing Evidence (areas where meaningful evidence exists but knowledge, consensus or application continues to evolve): using measured cardiorespiratory fitness as a routine risk marker [11], and longevity medicine as an organised clinical discipline [3].

  • Emerging Science (promising areas of scientific investigation requiring further validation): biological-age biomarkers such as epigenetic clocks [13][14].

  • Investigational Applications (approaches that remain experimental or subject to regulatory, ethical or scientific limitations): medicines and supplements given to slow ageing itself [15][16][17].

These placements reflect the sources cited here. They may change as new trials report.

What is not proven?

No medicine or supplement has yet been shown in large human trials to slow ageing or extend healthspan in healthy people. Several are being studied [4][15].

Rapamycin (sirolimus) has approved medical uses for specified conditions. In the United States these are preventing organ rejection after kidney transplant and treating lymphangioleiomyomatosis, a rare lung disease [21]. It extends health and lifespan in several animal species [15], but that does not establish an approved or proven anti-ageing use in healthy people [4]. A 2023 review says questions remain before such drugs could become standard care; both its authors declare links to companies developing them [15].

In the PEARL trial, 114 healthy adults completed 48 weeks of weekly low-dose rapamycin or placebo. PEARL found no statistically significant between-group benefit on its primary outcome, visceral fat (fat around the internal organs). Some secondary measures improved in subgroups, which are exploratory findings [16]. The trial was small, and several of its authors are employees and shareholders of the company that ran it [16].

Metformin is a long-established diabetes medicine [17]. The TAME (Targeting Aging with Metformin) trial was designed to enrol 3,000 adults aged 65 to 79 at about 14 US centres [17]. It would test whether metformin delays a combined outcome of heart disease, cancer, dementia and death [17]. The cited 2024 sponsor update described fundraising to launch the trial [18]. Searches of ClinicalTrials.gov and PubMed on 11 October 2026 found no TAME registration or published results [22][23].

Supplements marketed against ageing have thin human evidence [4][19]. A 2026 meta-analysis of nicotinamide mononucleotide (NMN), a precursor of the coenzyme NAD+, found short-term use well tolerated. It found no clear benefit for weight, glucose, HbA1c or lipids [19]. A 2024 review found human evidence for resveratrol and alpha-ketoglutarate similarly limited [4].

How does it relate to preventive and lifestyle medicine?

Longevity medicine overlaps heavily with both. Its distinct feature is its focus on ageing biology as the shared cause of many diseases.

Preventive medicine aims to stop disease before it starts. Lifestyle medicine uses therapeutic lifestyle change as a primary treatment. Its six pillars are a whole-food, plant-predominant diet, physical activity, restorative sleep, stress management, avoiding risky substances and social connection [20].

Longevity medicine adds the geroscience view and an interest in measuring biological ageing [3][8]. Its best-supported actions are the same ones preventive and lifestyle medicine already use.

GFRMI aims to distinguish established evidence, developing evidence, emerging science and investigational applications throughout its Knowledge content.

Frequently asked questions

Is longevity medicine a recognised medical specialty in India? The National Medical Commission (NMC) postgraduate lists in the Post-Graduate Medical Education Regulations, 2023 (PGMER-2023) do not name longevity medicine as a qualification; they do list MD (Geriatrics) [24]. Separately, scientific sources describe it as an emerging field or clinical framework without a single agreed definition [3][4]. Those descriptions do not settle its legal status in any country.

Are biological age tests ready for routine clinical use? Commercial biological-age scores are not established substitutes for validated clinical risk assessment, or validated tools for choosing anti-ageing treatment. Conventional clocks can also vary between repeat samples [13][14].

Do metformin or rapamycin slow ageing in humans? This has not been shown. No TAME results for metformin were found as of 11 October 2026 [22][23]. The PEARL trial of rapamycin in healthy adults was small, lasted under a year and found no significant benefit on its primary outcome [16].

References

All sources accessed 11 October 2026.

  1. Zhavoronkov A, Bischof E, Lee KF. Artificial intelligence in longevity medicine. Nature Aging. 2021;1(1):5-7. https://doi.org/10.1038/s43587-020-00020-4

  2. Bischof E, Scheibye-Knudsen M, Siow R, Moskalev A. Longevity medicine: upskilling the physicians of tomorrow. The Lancet Healthy Longevity. 2021;2(4):e187-e188. https://doi.org/10.1016/S2666-7568(21)00024-6

  3. Bischof E, Wilczok D, Kirkland JL, Wilaksono B, et al. Upskilling in healthy longevity medicine and its association with physicians’ implementation intent and self-reported clinical confidence: cross-sectional observational study. JMIR Medical Education. 2026;12:e83779. https://pmc.ncbi.nlm.nih.gov/articles/PMC13002000/

  4. Martinović A, Mantovani M, Trpchevska N, Novak E, et al. Climbing the longevity pyramid: overview of evidence-driven healthcare prevention strategies for human longevity. Frontiers in Aging. 2024;5:1495029. https://pmc.ncbi.nlm.nih.gov/articles/PMC11628525/

  5. Garmany A, Terzic A. Global healthspan-lifespan gaps among 183 World Health Organization member states. JAMA Network Open. 2024;7(12):e2450241. https://pmc.ncbi.nlm.nih.gov/articles/PMC11635540/

  6. World Health Organization. Healthy ageing and functional ability (questions and answers). WHO; 2020. https://www.who.int/news-room/questions-and-answers/item/healthy-ageing-and-functional-ability

  7. UNFPA India and International Institute for Population Sciences. India Ageing Report 2023. UNFPA; 2023. https://india.unfpa.org/sites/default/files/pub-pdf/20230926_india_ageing_report_2023_web_version_.pdf

  8. Kennedy BK, Berger SL, Brunet A, Campisi J, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709-713. https://pmc.ncbi.nlm.nih.gov/articles/PMC4852871/

  9. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278. https://doi.org/10.1016/j.cell.2022.11.001

  10. Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health. Circulation. 2022;146(5):e18-e43. https://pmc.ncbi.nlm.nih.gov/articles/PMC10503546/

  11. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open. 2018;1(6):e183605. https://pmc.ncbi.nlm.nih.gov/articles/PMC6324439/

  12. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics. 2018;19(6):371-384. https://doi.org/10.1038/s41576-018-0004-3

  13. Higgins-Chen AT, Thrush KL, Wang Y, Minteer CJ, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. Nature Aging. 2022;2(7):644-661. https://pmc.ncbi.nlm.nih.gov/articles/PMC9586209/

  14. Moqri M, Herzog C, Poganik JR, Ying K, et al. Validation of biomarkers of aging. Nature Medicine. 2024;30(2):360-372. https://pmc.ncbi.nlm.nih.gov/articles/PMC11090477/

  15. Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging. 2023;3(6):642-660. https://pmc.ncbi.nlm.nih.gov/articles/PMC10330278/

  16. Moel M, Harinath G, Lee V, Nyquist A, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. https://pmc.ncbi.nlm.nih.gov/articles/PMC12074816/

  17. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metabolism. 2016;23(6):1060-1065. https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/

  18. American Federation for Aging Research. AFAR initiative in the news: NPR spotlights TAME Trial and AFAR scientific leadership. AFAR; 2024. https://www.afar.org/news/afar-initiative-in-the-news-npr-spotlights-tame-trial-and-afar-scientific-leadership

  19. Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients. 2026;18(14):2251. https://pmc.ncbi.nlm.nih.gov/articles/PMC13414721/

  20. Lippman D, Stump M, Veazey E, Guimarães ST, et al. Foundations of lifestyle medicine and its evolution. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2024;8(1):97-111. https://pmc.ncbi.nlm.nih.gov/articles/PMC10831813/

  21. Wyeth Pharmaceuticals (Pfizer). Rapamune (sirolimus) prescribing information. US Food and Drug Administration; revised 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf

  22. ClinicalTrials.gov. Search results for “Targeting Aging with Metformin”. US National Library of Medicine; searched 11 October 2026. https://clinicaltrials.gov/search?term=%22Targeting%20Aging%20with%20Metformin%22

  23. PubMed. Search results for TAME[tiab] AND metformin[tiab]. US National Library of Medicine; searched 11 October 2026. https://pubmed.ncbi.nlm.nih.gov/?term=TAME%5Btiab%5D+AND+metformin%5Btiab%5D

  24. National Medical Commission, Post-Graduate Medical Education Board. Post-Graduate Medical Education Regulations, 2023 (PGMER-2023), Annexures. NMC; 29 December 2023. https://nmc.org.in/storage/cms/rules-regulation-nmc/V2DvjM4NiDLYroNAyPmg0KK95sLUTMnWbjTdcDO2.pdf